US · OMCL · MEDICAL - EQUIPMENT & SERVICES
Omnicell, Inc. (OMCL) intrinsic value and stock valuation
$32.51as of 2026-11-21 · Mkt cap 1.67B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Omnicell, Inc. DCF and intrinsic value
InvestorsCraft values OMCL with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from OMCL’s statements →
Omnicell, Inc. Graham Number
Graham Number: $5.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- 10x Genomics, Inc. (TXG) $51.80
- UFP Technologies, Inc. (UFPT) $290.85
- Progyny, Inc. (PGNY) $35.71
- Astrana Health, Inc. (ASTH) $28.90
- Omada Health (OMDA) $11.87
- Schrödinger, Inc. (SDGR) $22.93
- Teladoc Health, Inc. (TDOC) $7.45
- GoodRx Holdings, Inc. (GDRX) $2.92
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.18B | $1.11B | $1.15B | $1.3B | $1.13B |
| Operating income | $11.7M | $340K | -$-19.33M | -$-2.32M | $89.5M |
| Net income | $2.05M | $12.5M | -$-20.37M | $5.65M | $77.9M |
| EPSd | $44.2K | $270.9K | -$-450.56K | $123.1K | $1.62M |
| Operating cash flow | $127.3M | $187.7M | $181.1M | $77.8M | $231.8M |
| Capital expenditure | -$-40.41M | -$-36.46M | -$-41.47M | -$-60.74M | -$-28.97M |
| Free cash flow | $86.9M | $151.3M | $139.6M | $17M | $202.8M |
| Total assets | $1.97B | $2.12B | $2.23B | $2.21B | $2.14B |
| Total debt | $204.3M | $382.6M | $614.1M | $616.7M | $541M |
| Net debt | $7.83M | $13.4M | $146.1M | $286.4M | $192M |
| Total equity | $1.23B | $1.24B | $1.19B | $1.13B | $1.15B |
| Cash and short-term investments | $211.2M | $381.7M | $479.8M | $341.9M | $359.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.18B | $1.11B | $1.15B | $1.3B | $1.13B |
| Cost of revenue | $676.8M | $641.2M | $647.2M | $707M | $577.4M |
| Gross profit | $508M | $471M | $499.9M | $589M | $554.7M |
| Research and development expenses | $87.7M | $90.4M | $93.3M | $105M | $75.7M |
| Selling, general and administrative expenses | $408.6M | $380.3M | $426M | $486.3M | $389.4M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $496.4M | $470.7M | $519.3M | $591.3M | $465.2M |
| Cost and expenses | $1.17B | $1.11B | $1.17B | $1.3B | $1.04B |
| Interest income | $11.9M | $24.9M | $14.8M | $0.00 | $0.00 |
| Interest expense | $3.91M | $4.53M | $0.00 | $130K | $22.4M |
| Depreciation and amortization | $86.6M | $89.8M | $95.6M | $99.2M | $84.9M |
| Ebitda | $101.9M | $119.9M | $80M | $96.9M | $173.3M |
| Operating income | $11.7M | $340K | -$-19.33M | -$-2.32M | $89.5M |
| Total other income/expenses, net | -$-340K | $25.3M | -$-780K | -$-130K | -$-23.5M |
| Income before tax | $11.3M | $25.6M | -$-20.11M | -$-2.45M | $66M |
| Income tax expense | $9.27M | $13.1M | $260K | -$-8.1M | -$-11.84M |
| Net income | $2.05M | $12.5M | -$-20.37M | $5.65M | $77.9M |
| Weighted average shares outstanding | $46M | $46.1M | $45.2M | $44.4M | $43.5M |
| Weighted average diluted shares outstanding | $46.4M | $46.3M | $45.2M | $45.9M | $47.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $211.2M | $381.7M | $479.8M | $341.9M | $359.7M |
| Net receivables | $216.9M | $256.4M | $252M | $299.5M | $240.9M |
| Inventory | $100.9M | $88.7M | $110.1M | $147.6M | $119.9M |
| Total current assets | $680.1M | $815.5M | $927.6M | $881.8M | $780.7M |
| Property, plant and equipment, net | $144.5M | $138.3M | $133.6M | $132M | $119.7M |
| Goodwill and intangible assets | $962.3M | $981.4M | $1.01B | $1.06B | $1.11B |
| Long-term investments | $60.7M | $52.7M | $43M | $32.9M | $18.4M |
| Total non-current assets | $1.29B | $1.31B | $1.3B | $1.33B | $1.36B |
| Total assets | $1.97B | $2.12B | $2.23B | $2.21B | $2.14B |
| Accounts payable | $44M | $51.8M | $45M | $63.4M | $71.5M |
| Short-term debt | $12M | $185M | $10.5M | $10.8M | $501.1M |
| Deferred revenue | $283.5M | $202M | $175.9M | $187.2M | $152.1M |
| Total current liabilities | $476.6M | $595.7M | $367.8M | $428.5M | $876.2M |
| Long-term debt | $192.4M | $197.5M | $603.6M | $606M | $39.9M |
| Deferred revenue, non-current | $63.3M | $76.1M | $58.6M | $37.4M | $20.2M |
| Total non-current liabilities | $266.3M | $282M | $670.1M | $652.2M | $119.7M |
| Capital lease obligations | $36.8M | $41.8M | $44.4M | $50.2M | $52.9M |
| Total liabilities | $742.9M | $877.7M | $1.04B | $1.08B | $995.8M |
| Common stock | $60K | $60K | $60K | $60K | $50K |
| Retained earnings | $384.9M | $382.9M | $370.4M | $390.7M | $368.6M |
| Accumulated other comprehensive income (loss) | -$-8.85M | -$-17.2M | -$-13.43M | -$-17.09M | -$-8.41M |
| Total equity | $1.23B | $1.24B | $1.19B | $1.13B | $1.15B |
| Total investments | $75.4M | $65.2M | $54.8M | $44.4M | $29.1M |
| Total debt | $204.3M | $382.6M | $614.1M | $616.7M | $541M |
| Net debt | $7.83M | $13.4M | $146.1M | $286.4M | $192M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.05M | $12.5M | -$-20.37M | $5.65M | $77.9M |
| Depreciation and amortization | $86.6M | $89.8M | $95.6M | $99.2M | $84.9M |
| Stock-based compensation | $44.5M | $39.3M | $55.3M | $68.3M | $53.2M |
| Change in working capital | -$-8.33M | $58.3M | $43.7M | -$-73.47M | -$-3.34M |
| Accounts receivable | $41.4M | -$-5M | $38.7M | -$-60.36M | -$-40.97M |
| Inventory | -$-11.22M | $5.39M | $38M | -$-30.11M | -$-25.7M |
| Accounts payable | -$-9.28M | $7.21M | -$-17.52M | -$-7.75M | $29.1M |
| Net cash provided by operating activities | $127.3M | $187.7M | $181.1M | $77.8M | $231.8M |
| Investments in property, plant and equipment | -$-40.41M | -$-36.46M | -$-55.02M | -$-60.74M | -$-28.97M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $2.07M | -$-354.16M |
| Net cash used for investing activities | -$-60.36M | -$-52.79M | -$-55.02M | -$-58.67M | -$-412.5M |
| Common stock issued | $16.9M | $38.6M | $23.2M | $40.2M | $0.00 |
| Common stock repurchased | -$-77.6M | $0.00 | $0.00 | -$-52.21M | -$-16.29M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-218.32M | -$-235.58M | $23.4M | -$-20.95M | $47.4M |
| Net change in cash | -$-147.58M | -$-102.36M | $148.1M | -$-2.79M | -$-134.3M |
| Cash at end of period | $251M | $398.6M | $501M | $352.8M | $355.6M |
| Operating cash flow | $127.3M | $187.7M | $181.1M | $77.8M | $231.8M |
| Capital expenditure | -$-40.41M | -$-36.46M | -$-41.47M | -$-60.74M | -$-28.97M |
| Free cash flow | $86.9M | $151.3M | $139.6M | $17M | $202.8M |
Line items
Line items
Line items
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
- CEO
- Randall A. Lipps
- Employees
- 3.58K
- Beta
- 0.97
Included in
Explore
Frequently asked questions
What is the intrinsic value of Omnicell, Inc. (OMCL)?
Omnicell, Inc. (OMCL) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OMCL undervalued?
OMCL trades at a price of $32.51 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.